云知声股价大幅波动，大模型业务成增长引擎

Core Viewpoint - The recent stock price volatility of Cloud Wisdom (09678.HK) is driven by high growth expectations in its large model business, technological breakthroughs, and commercial progress, despite ongoing losses and cash flow pressures [1][5]. Stock Performance - Cloud Wisdom's stock experienced significant fluctuations in February 2026, with a single-day increase of 16.77% on February 12, closing at HKD 345.40, followed by a 1.45% rise on February 13, closing at HKD 350.40 [1]. - Over the last five trading days, the cumulative increase was 20.33%, and over the last twenty trading days, it was 25.05%, although the stock is down 13.35% year-to-date [1]. - The stock exhibited a daily volatility of 11.58% on February 12, with a range volatility of 39.33% [1]. Business Progress - Cloud Wisdom has made significant advancements in the medical AI sector, with its "Shan Hai. Zhi Yi" large model achieving top rankings in three categories during the MedBench 4.0 evaluation [3]. - On February 6, 2026, the company entered a strategic partnership with Jia Hui Medical to expand into the high-end medical market [3]. - The company released the "Shan Hai. Zhi Yin Model 2.0," which supports full-duplex interaction and has achieved an accuracy rate of over 90% in recognizing complex background sounds [3]. Financial Situation - On February 13, 2026, the net outflow of funds was HKD 466.42 million from institutional investors and HKD 337.91 million from retail investors [4]. - The current price-to-earnings ratio (TTM) is -47.17, and the price-to-book ratio is 17.59, indicating a high market valuation expectation [4]. - Zhongsheng Group has set a target price of HKD 750.58 based on a 25x price-to-sales ratio for 2026 [4]. Future Development - The company faces risks related to slower-than-expected R&D progress and insufficient cash flow, with cash reserves projected to be only HKD 1.56 billion by the end of 2024, against a net loss of HKD 4.54 billion for that year [5]. - The customer retention rate in the medical business has declined from 70.4% in 2022 to 53.3% in 2024, indicating a need for improved customer stability [5].